Mode
Text Size
Log in / Sign up

Systematic review of Dendrobium phenanthrene bioactivity across multiple disease modelsScientists found many plant chemicals that fight cancer and help diabetes in lab tests

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that in vitro Dendrobium phenanthrene data do not yet confirm clinical therapeutic potential.

This systematic review assesses the bioactivity of 158 phenanthrene metabolites isolated from 53 Dendrobium taxa. The scope covers potential activities relevant to cancer, diabetes mellitus, metabolic dysfunction-associated fatty liver disease, osteoarthritis, and thrombosis. Among the 158 metabolites, 64 compounds (40.5%) have been evaluated in at least one bioactivity assay. The majority (54 of 64, 84.4%) are supported solely by in vitro screening data, often with IC50 values less than 100 μM.

Only 8 compounds (12.5%) have validated mechanisms, while 4 compounds (6.2%) demonstrate in vivo efficacy in animal models. The review identifies secondary outcomes such as anti-tumor, anti-inflammatory, antioxidant, antidiabetic, anti-fibrotic, antiplatelet, and antimicrobial activities. However, the authors explicitly state that the research reflects intensity rather than therapeutic potential.

Key limitations include significant heterogeneity in assay systems, the absence of standardized activity thresholds across studies, limited in vivo validation, and a lack of pharmacokinetic data. Safety data, adverse events, and tolerability were not reported. The review does not provide specific dosing or clinical trial data, and the certainty of clinical benefit remains uncertain due to these gaps.

Practitioners should interpret these findings as preliminary evidence of biological activity in laboratory settings. The absence of pharmacokinetic data and standardized thresholds limits the ability to translate these in vitro or animal model results into clinical recommendations for patients with the listed conditions.

Researchers looked at one hundred fifty eight different chemicals found in Dendrobium plants. They checked how these substances might help with serious health problems like cancer, diabetes, and liver disease. The study is a review of many different reports about these plant products.

About sixty four of the chemicals were tested for their effects. Most of these tests were done in a lab using cells. This means the results show what happens in a dish, not inside a person. Only eight chemicals had their specific way of working clearly explained by scientists.

Just four chemicals showed they could work inside living animals. This is a small number compared to all the chemicals checked. The review also noted that different labs use different ways to test things. This makes it hard to compare results from different studies easily.

More work is needed to see if these plants can help people safely. We do not know how the body handles these chemicals over time. Future studies must test these products in people to know if they are safe and effective.

What this means for you:
Lab tests show promise for plant chemicals, but human safety and effectiveness need more study.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
For millennia, Dendrobium Sw., the second-largest genus of Orchidaceae, has been widely applied in traditional Chinese medicine to nourish yin, clear heat, and promote body fluid. Its stems are a rich source of phenanthrenes, which are low molecular weight polycyclic aromatic metabolites with remarkable structural diversity and broad-spectrum bioactivities. This review provides the first comprehensive and systematic analysis of 158 naturally occurring phenanthrenes isolated from 53 Dendrobium taxa (51 species, 1 variety, and 1 horticultural cultivar) based on an extensive literature survey of international and Chinese databases (PubMed, Web of Science, SciFinder, CNKI, etc.) from 1987 to 2025. The article summarizes pharmacopoeial records, classical texts, and theses. The identified metabolites include simple phenanthrenes, 9,10-dihydrophenanthrenes, diphenanthrene dimers, phenanthrenequinones, and other phenanthrene derivatives, often functionalized with hydroxyl, methoxyl, and carboxyl functionalities. Among 158 phenanthrene metabolites isolated from Dendrobium species, 64 compounds (40.5%) have been evaluated in at least one bioactivity assay, with reported activities spanning anti-tumor (cytotoxic), anti-inflammatory, antioxidant, antidiabetic, anti-fibrotic, antiplatelet, or antimicrobial endpoints. However, the majority (54/64, 84.4%) are supported solely by in vitro screening data (IC50 < 100 μM in cell-based assays), while only 8 compounds (12.5%) have validated mechanisms and a mere 4 compounds (6.2%) demonstrate in vivo efficacy in animal models. This quantitative summary reflects research intensity rather than therapeutic potential, given significant heterogeneity in assay systems and the absence of standardized activity thresholds across studies. Mechanistic studies have revealed that these compounds modulate key signaling. thereby offering therapeutic potential against cancer, diabetes mellitus, metabolic dysfunction-associated fatty liver disease (MAFLD), osteoarthritis, and thrombosis. Despite the bioactivity profile, clinical translation is limited by in vivo validation and the lack of pharmacokinetic data. Future studies should focus on systematic preclinical evaluation. Multi-omics mechanistic studies are needed to advance these natural scaffolds into clinically viable therapeutics.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.